Genmab A/s
No standout activity across the feeds we track.
What this band has actually done: stocks scoring 0–25 beat the S&P 500 over the next three months 39.9% of the time, across 100,496 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic…
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2026-03-30 | Alan Armstrong · R-OK | Senate | Bought | $1,001 - $15,000 |
| 2025-01-16 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2024-12-16 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2024-07-19 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2024-06-18 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2023-10-16 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2023-09-15 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2023-07-20 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2023-07-19 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2023-07-10 | Daniel S. Goldman · D-NY | House | Sold | $50,001 - $100,000 |
Show the other 2
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2023-03-31 | Daniel S. Goldman · D-NY | House | Sold | $1,001 - $15,000 |
| 2020-11-20 | Thomas R. Carper · D-DE | Senate | Bought | $1,001 - $15,000 |
Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.